Truist Financial analyst Srikripa Devarakonda maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and sets the target price at $1,126.
According to TipRanks data, the analyst has a success rate of 51.6% and a total average return of 12.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's recent quarterly results surpassed expectations slightly in revenue and more significantly in earnings per share. However, these results were overshadowed by the performance of the company's Eylea franchise. The impending introduction of a biosimilar version of Eylea by a competitor has raised concerns about the future prospects of the franchise, including potential underestimation by the market of the erosion of standard dose sales and possible negative impact on the high dose variant.
The recent decline in Regeneron shares is considered excessive, stemming from what is perceived as an overreaction to the Pavblu news, a less than favorable forecast for Q4 Eylea HD, and uncertainties surrounding future Eylea growth.
The stock's significant drop after Q3 earnings was somewhat unexpected. It was previously thought that the near- and long-term consensus estimates for the ophthalmology franchise were overly optimistic. However, it is believed that the fundamental fair value of Regeneron is currently well above its market value.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
儲億銀行分析師Srikripa Devarakonda維持$再生元製藥公司 (REGN.US)$買入評級，目標價1,126美元。
根據TipRanks數據顯示，該分析師近一年總勝率為51.6%，總平均回報率為12.5%。
此外，綜合報道，$再生元製藥公司 (REGN.US)$近期主要分析師觀點如下：
Regeneron最近的季度業績超出了營業收入稍微，收益每股則更顯著。然而，這些成績卻被該公司Eylea系列的表現所掩蓋。競爭對手即將推出Eylea的生物類似藥版本，引發市場對該系列未來前景的擔憂，包括市場對標準劑量銷售侵蝕和高劑量變體可能帶來的負面影響的可能低估。
Regeneron股價近期下跌被認爲過度，源於對Pavblu消息的過度反應，Q4 Eylea HD的不那麼樂觀的預測，以及對未來Eylea增長的不確定性。
該股票在第三季度收益之後的顯著下跌有些出乎意料。之前曾認爲眼科醫療系列的近期和長期共識預測過於樂觀。然而，現在認爲Regeneron的基本公允價值目前遠高於其市場價值。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
